NUE

Nuevolution

Market Cap 767.2M

Nuevolution is a Copenhagen-based biopharmaceutical company, co-founded in 2001 by CEO Alex Haahr Gouliaev and today listed in Stockholm, Sweden. NUE uses its proprietary drug discovery platform Chemetics to generate novel small molecule drugs for hard-to-drug disease targets. The platform allows NUE to pursue multiple disease targets cost effectively and offers increased efficiency and quality of drug discovery. The business model revolves around Chemetics and two distinct value-drivers; (1) risk-sharing/”pre-sale” partnership deals to identify drugs for novel targets in collaboration with a partner, and (2) the development and out-licensing of internal projects. Revenues are generated from upfront and milestone payments as well as recurring royalties on future sales. NUE has earned about SEK 525 million in licensing revenue from 17 partner agreements to date and current deal structures offer multiple milestone opportunities in the coming years. The Company has delivered on their IPO promise of delivering deals as they signed a multi-target risk-sharing partnership with Amgen in October 2016 and out-licensed a program to Almirall in December 2016. Given the portfolio approach, NUE does not fall into the category of fully binary biotech companies, but rather into a class of more stable biopharma companies with some growth visibility. 

+ more
Today
Day High
18.40
17.7
Day Low
17.40
Day Open
18.30
Prev Close
17.90
VWAP
18.1
Volume
14K
Turnover
0.262M
Top Broker
EPB
VWAP
18.2
Avg Volume
18K
Avg Turnover
0.331M
Top Brokers
NON/AVA
VWAP
19.5
Avg Volume
28K
Avg Turnover
0.543M
Top Brokers
NON/AVA
VWAP
19.2
Avg Volume
29K
Avg Turnover
0.563M
Top Brokers
AVA/NON
52 week summary
Price Range
9.6
Last
24.0
Beta
N/A
Market Cap
767.2M
Total Return
78.1%
Trailing P/E
N/A
Div Yield
0.0%
Shares Outstanding
42.9M
Next Earnings Date
9 Feb
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.


Relative Price Strength
Change 3 Months 9.4%
Change 12 Months 62.6%
Volume Trend
Average Volume 10 vs 60 Days -74.9%
Price VS
52 Week High -26.3%
50 Day Moving Average -8.9%
200 Day moving Average 3.7%

Add article markers

Compare Nuevolution to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Alex Haahr Gouliaev, CEO
  • Henrik D. Simonsen, CFO
  • Thomas Franch, CSO
  • Antonius (Ton) Berkien, CBO
  • Executive board
  • Stig Løkke Pedersen, Chairman of the board
  • Søren Lemonius
  • Lars Henriksson
  • Jutta Heim
  • Jeanette M. Wood
Last updated: 2017-03-30 Source: Redeye
Major Owners Equity Votes
SEB Venture Capital 23.5%
23.5%
Sunstone Capital 20.8%
20.8%
Industrifonden 20.0%
20.0%
SEB Utvecklingsstiftelse 7.7%
7.7%
LMK Forward 3.2%
3.2%
Avanza Pensionsförsäkring AB 2.8%
2.8%
SEB Pensionsstiftelsen 2.7%
2.7%
Nordnet Pensionförsäkring 1.1%
1.1%
Claus Resen Steenstrup and family 0.8%
0.8%
Henry Dunkers Förvaltning 0.7%
0.7%
Last updated: 2017-09-11 Source: Redeye/Holdings
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2014
  •  
  • -131.6%
  • -154.5%
  • -185.7%
  • -214.1%
  • -217.8%
  • -183.7%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • -45.5
  • 0.0
  • 0.0
  • 0.0
  • -1.5
  • 0.7
  • 0.7
  • 0.0
  •  
  • 71.9%
  • 100.0%
  • -45
  • 6
  • 0.4
  • 2014
  •  
  •  
  • 46
  • 3
  • 7
  • 3
  • 59
  •  
  • 3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2
  • 4
  • 8
  • 72
  •  
  •  
  • 1
  • 9
  • 9
  • 19
  • 0
  • 1
  • 0
  • 20
  • 0
  • 0
  • 52
  • 0
  • 52
  • 72
  • 2014
  • 30
  • -94
  • -1
  • -65
  • 8
  • -57
  • 1
  • -56
  • 30
  • -1
  • -32
  • 2014 Q3
  • 30
  • -94
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2014 Q4
  • 30
  • -94
  • -64
  • -1
  • 0
  • 0
  • -65
  • 0
  • 3
  • 0
  • -62
  • 7
  • -55
  • 2015
  •  
  • -116.2%
  • -120.7%
  • -2,382.5%
  • -706.4%
  • -712.6%
  • -680.3%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • -204.7
  • 0.0
  • 0.0
  • 0.0
  • -9.6
  • 1.4
  • 1.3
  • 0.0
  •  
  • 84.3%
  • 100.0%
  • -205
  • -7
  • 0.1
  • 2015
  •  
  •  
  • 206
  • 0
  • 0
  • 7
  • 213
  •  
  • 5
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2
  • 7
  • 14
  • 235
  •  
  •  
  • 1
  • 12
  • 20
  • 33
  • 0
  • 3
  • 0
  • 37
  • 0
  • 0
  • 198
  • 0
  • 198
  • 235
  • 2015
  • 21
  • -172
  • -1
  • -152
  • 7
  • -145
  • 1
  • -144
  • 20
  • -4
  • -132
  • 2015 Q1
  • 21
  • -172
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q2
  • 21
  • -172
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 21
  • -172
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 21
  • -172
  • -151
  • -1
  • 0
  • 0
  • -152
  • 0
  • -0
  • 0
  • -152
  • 7
  • -145
  • 2016
  •  
  • -13.9%
  • -5.7%
  • 122.5%
  • -8.7%
  • -8.7%
  • -21.2%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • -178.1
  • 0.0
  • 0.0
  • 0.0
  • -1.5
  • 17.0
  • 17.0
  • 0.0
  •  
  • 84.3%
  • 100.0%
  • -178
  • -8
  • 0.6
  • 2016
  •  
  •  
  • 180
  • 10
  • 0
  • 0
  • 190
  •  
  • 6
  • 0
  • 0
  • 0
  • 0
  • 0
  • 6
  • 12
  • 0
  • 202
  •  
  •  
  • 1
  • 20
  • 8
  • 29
  • 0
  • 3
  • 0
  • 32
  • 0
  • 0
  • 170
  • 0
  • 170
  • 202
  • 2016
  • 120
  • -131
  • 0
  • -10
  • 2
  • -8
  • 0
  • -8
  • -8
  • -5
  • -25
  • 2016 Q1
  • 2
  • -30
  • -28
  • 0
  • 0
  • 0
  • -28
  • 0
  • 0
  • 0
  • -27
  • 2
  • -26
  • 2016 Q2
  • 111
  • -35
  • 76
  • 0
  • 0
  • 0
  • 76
  • 0
  • 1
  • 0
  • 77
  • -21
  • 56
  • 2016 Q3
  • 2
  • -31
  • -30
  • 0
  • 0
  • 0
  • -30
  • 0
  • -0
  • 0
  • -30
  • 1
  • -29
  • 2016 Q4
  • 6
  • -35
  • -29
  • 0
  • 0
  • 0
  • -29
  • 0
  • -0
  • 0
  • -29
  • 2
  • -27
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2017-09-29 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.


Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.